Werner Keenswijk1,2, Ann Raes3, Johan Vande Walle3. 1. Department of Pediatrics, Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium. keenswijkwerner@yahoo.com. 2. Department of Pediatrics, Diakonessenhuis , Paramaribo, Suriname. keenswijkwerner@yahoo.com. 3. Department of Pediatrics, Pediatric Nephrology, Ghent University Hospital, Ghent, Belgium.
Abstract
Severe complications due to Shigatoxin-associated hemolytic uremic syndrome (STEC-HUS) currently present a serious challenge since no specific treatment for this condition is available. Eculizumab, a terminal complement inhibitor, has been used especially in STEC-HUS patients with severe neurological involvement, but the efficacy remains undetermined. In order to determine its efficacy, we searched the databases Pubmed, Web of Science, Embase, and LiLACS for reports describing outcomes of eculizumab administration in STEC-HUS. We retrieved 11 reports ranging from case reports to cohort studies with the largest study population emanating from the 2011 German outbreak. Outcomes were variable and difficult to interpret in light of the absence of high-quality studies but seemed to point towards potential efficacy of eculizumab if administered early in the course. CONCLUSION: The efficacy of eculizumab in STEC-HUS could not be established nor disproven based on current data, and there is a desperate need for randomized controlled trials. What is known? • Eculizumab has been used in complicated cases of Shigatoxin-associated hemolytic uremic syndrome but the efficacy remains unknown? What is new? • Eculizumab might be efficacious if given early in selected cases of Shigatoxin-associated hemolytic uremic syndrome; however, randomized trials are needed to assess this.
Severe complications due to Shigatoxin-associated hemolytic uremic syndrome (STEC-HUS) currently present a serious challenge since no specific treatment for this condition is available. Eculizumab, a terminal complement inhibitor, has been used especially in STEC-HUSpatients with severe neurological involvement, but the efficacy remains undetermined. In order to determine its efficacy, we searched the databases Pubmed, Web of Science, Embase, and LiLACS for reports describing outcomes of eculizumab administration in STEC-HUS. We retrieved 11 reports ranging from case reports to cohort studies with the largest study population emanating from the 2011 German outbreak. Outcomes were variable and difficult to interpret in light of the absence of high-quality studies but seemed to point towards potential efficacy of eculizumab if administered early in the course. CONCLUSION: The efficacy of eculizumab in STEC-HUS could not be established nor disproven based on current data, and there is a desperate need for randomized controlled trials. What is known? • Eculizumab has been used in complicated cases of Shigatoxin-associated hemolytic uremic syndrome but the efficacy remains unknown? What is new? • Eculizumab might be efficacious if given early in selected cases of Shigatoxin-associated hemolytic uremic syndrome; however, randomized trials are needed to assess this.
Authors: Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer Journal: N Engl J Med Date: 2011-05-25 Impact factor: 91.245
Authors: Sebastian Loos; Thurid Ahlenstiel; Brigitta Kranz; Hagen Staude; Lars Pape; Christoph Härtel; Udo Vester; Laura Buchtala; Kerstin Benz; Bernd Hoppe; Ortraud Beringer; Martin Krause; Dominik Müller; Martin Pohl; Johanna Lemke; Georg Hillebrand; Martin Kreuzer; Jens König; Marianne Wigger; Martin Konrad; Dieter Haffner; Jun Oh; Markus J Kemper Journal: Clin Infect Dis Date: 2012-06-05 Impact factor: 9.079
Authors: Jan Menne; Martin Nitschke; Robert Stingele; Mariam Abu-Tair; Jan Beneke; Jörn Bramstedt; Jan P Bremer; Reinhard Brunkhorst; Veit Busch; Reinhard Dengler; Günther Deuschl; Klaus Fellermann; Helmut Fickenscher; Christoph Gerigk; Alexander Goettsche; Jobst Greeve; Carsten Hafer; Friedrich Hagenmüller; Hermann Haller; Stefan Herget-Rosenthal; Bernd Hertenstein; Christina Hofmann; Melanie Lang; Jan T Kielstein; Ulrich C Klostermeier; Johannes Knobloch; Markus Kuehbacher; Ulrich Kunzendorf; Hendrik Lehnert; Michael P Manns; Tobias F Menne; Tobias N Meyer; Claus Michael; Thomas Münte; Christine Neumann-Grutzeck; Jens Nuernberger; Hermann Pavenstaedt; Leyla Ramazan; Lutz Renders; Jonas Repenthin; Wolfgang Ries; Axel Rohr; Lars Christian Rump; Ola Samuelsson; Friedhelm Sayk; Bernhard M W Schmidt; Sabine Schnatter; Harald Schöcklmann; Stefan Schreiber; Cay U von Seydewitz; Jürgen Steinhoff; Sylvia Stracke; Sebastian Suerbaum; Andreas van de Loo; Martin Vischedyk; Karin Weissenborn; Peter Wellhöner; Monika Wiesner; Sebastian Zeissig; Jürgen Büning; Mario Schiffer; Tanja Kuehbacher Journal: BMJ Date: 2012-07-19
Authors: Dejan Lavrek; Sebastiano A G Lava; Gregorio P Milani; Giacomo D Simonetti; Mario G Bianchetti; Olivier Giannini Journal: J Nephrol Date: 2018-10-17 Impact factor: 3.902